· Revalyxis™ Platform · Partnering with pharma and biotech worldwide
The body knows how to heal. It just needs better tools.
Alvion Bio supplies pharma and biotech with highly potent stem cells, enabling the next generation of treatments for inflammatory and autoimmune disease.
Scroll to learn more
↓
The common thread in modern disease.
Inflammation: Immune response that never switches off for millions, causing debilitating chronic conditions like RA, Lupus, and MS.
Prevalence: Incidence is rising globally, driven by ageing populations, environmental stressors, and sophisticated diagnostics.
The Gap: Over 60% of patients on first-line therapies never reach durable remission, driving high human and economic costs.
Today’s drugs suppress. They don’t reset.
Suppression: Current biologics and small molecules block inflammatory signals but do not correct the underlying immune imbalance.
Resetting: Living cells restore natural regulatory capacity. MSCs communicate directly with the immune system to calm inflammation.
Bottlenecks: Donor tissue variability and biological age limit consistency. Clinical programmes need high-purity, scalable supply.
A fast-growing market with a critical supply gap.
The cell therapy market is projected to reach $290B by 2030, yet consistent clinical-grade manufacturing remains a critical constraint.
Alvion Bio bridges this gap, providing pharma with a reliable, scalable source of superior potent stem cells for next-gen treatments.
Market Projection
$290B
Estimated cell therapy market size by 2030